[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652224":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":25,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":25,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":25,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Pakistan Institute of Medical Sciences","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Montelukast","EXPERIMENTAL","Participants will receive montelukast 4 mg sachet orally once daily at night in addition to standard supportive care for acute bronchiolitis.",[13],"Drug: Montelukast",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","PLACEBO_COMPARATOR","Participants will receive placebo sugar granules orally once daily at night according to the same schedule as the montelukast group, in addition to standard supportive care for acute bronchiolitis",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Administrating montelukast to experimental group and monitoring response",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","Placebo sugar granules administered orally once daily at night according to the same schedule as montelukast 4 mg sachet, in addition to standard supportive care for acute bronchiolitis",[15],[31],{"name":32,"affiliation":5,"role":33},"Dr Haniyah Anwar","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Dr Haniyah Anwar, M.B.B.S","CONTACT","+92334-8359647","haniyahanwar@yahoo.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Pakistan Institute of Medical Sciences, Islamabad","RECRUITING","Islamabad","Federal","44000","Pakistan","PK",{"type":50,"coordinates":51},"Point",[52,53],73.04329,33.72148,{"lat":53,"lon":52},[56],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},{"type":33,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Haniyah Anwar","Post Graduate Trainee, Children Hospital, PIMS","100652224","phase-2-evaluating-the-role-of-montelukast-in-management-of-acute-bronchiolitis-100652224",false,"NCT07770464","Evaluating The Role Of Montelukast In Management Of Acute Bronchiolitis","Inclusion Criteria\n\n* Age 4 weeks to 2 years\n* Both genders\n* Duration of respiratory symptoms less than 4 days\n* Clinical diagnosis of acute bronchiolitis according to the operational definition provided in the study protocol\n\nExclusion Criteria\n\n* History of asthma\n* Previous hospital admissions for respiratory illness\n* Use of asthma medications\n* Congenital heart disease\n* Bronchopulmonary dysplasia\n* Immunodeficiency\n* Immunosuppression\n* Radiological evidence of pneumonia, including infiltrates or patches on chest X-ray","ALL","4 Weeks","2 Years",{"count":70,"type":71},60,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","This study aims to evaluate the role of Montelukast in management of acute Bronchiolitis in indoor patient and how this drug shortens the duration of admission and improves symptoms",[77],"Acute Bronchiolitis","2026-08-17",{"date":80,"type":81},"2026-08-18","ACTUAL",{"date":83,"type":81},"2026-01-01",{"date":85,"type":71},"2026-09-30",{"name":5,"class":6},1]